PharmaNewsDaily.com | Archive | Pharma Industry News

Home » Archives by category » Pharma Industry News

Bayer to acquire US gene therapy company Asklepios BioPharmaceutical in $4bn deal

German pharma giant Bayer has agreed to acquire US clinical-stage gene therapy company Asklepios BioPharmaceutical in a deal worth up to $4 billion. The portfolio of Asklepios BioPharmaceutical features investigational pre-clinical and clinical stage candidates, which are being developed for the treatment of neuromuscular, cardiovascular, central nervous system, and metabolic diseases. Asklepios BioPharmaceutical was established […]

October 26, 2020No CommentRead More

Covid-19 mRNA vaccine : Precision Nanosystems gets funding boost from Canadian govt

October 24, 2020 No Comment

Precision Nanosystems (PNI) has received a funding boost of up to CAD 18.2 million from the Canadian government to develop a mRNA vaccine for Covid-19. The funding from Canada’s Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) will help the Vancouver-based biotech company to move its Covid-19 mRNA vaccine candidate to clinical trials. […]

Gilead Sciences wraps up $21bn acquisition of Immunomedics

October 24, 2020 No Comment

Gilead Sciences has wrapped up its previously announced $21 billion acquisition of New Jersey-based biopharma company Immunomedics. With the completion of the deal, Immunomedics has now become a fully-owned subsidiary of Gilead Sciences. The common stock of Immunomedics will be delisted from the Nasdaq Global Market. Immunomedics, which has been acquired for $88 per share […]

Endo International to acquire BioSpecifics Technologies for $658m

October 19, 2020 No Comment

Endo International has agreed to acquire BioSpecifics Technologies, a New York-based commercial-stage biopharma company, for $88.5 per share, or an estimated enterprise value of around $658 million. The Irish pharma company and BioSpecifics Technologies have been in a strategic partnership since 2004. BioSpecifics Technologies had developing a form of injectable collagenase clostridium histolyticum (CCH), which […]

Lilly to acquire SARM1 inhibitor developer Disarm Therapeutics

October 16, 2020 No Comment

Lilly acquisition of Disarm Therapeutics : Eli Lilly and Company (Lilly) has agreed to acquire Disarm Therapeutics, a biotech company based in Cambridge, Massachusetts, which is focused on developing a new class of disease-modifying treatments for patients with axonal degeneration. As per the terms of the deal, Lilly will pay an upfront payment of $135 […]

EC strikes deal for supply of JNJ-78436735 Covid-19 vaccine candidate

October 9, 2020 No Comment

Johnson & Johnson (J&J) said that the European Commission (EC) has approved an advance purchase agreement for securing 200 million doses of the JNJ-78436735 Covid-19 vaccine candidate (Ad26.COV2.S) developed by its subsidiary Janssen Pharmaceutical Companies. Currently, the JNJ-78436735 vaccine candidate is being evaluated in the phase 3 ENSEMBLE Covid-19 vaccine trial across certain countries. The […]

Bristol Myers Squibb to acquire MyoKardia to gain access to mavacamten

October 5, 2020 No Comment

Bristol Myers Squibb (BMS) has agreed to acquire California-based clinical-stage biopharma company MyoKardia for $13.1 billion, to gain access to the latter’s cardiovascular drug candidate mavacamten. The US pharma giant is offering to acquire MyoKardia for $225.00 per share in an all-cash deal. Mavacamten is being developed for the treatment of a chronic heart disease […]

Dr. Reddy’s launches Sapropterin Dihydrochloride Tablets generic version in US

October 4, 2020 No Comment

Indian pharma company Dr. Reddy’s Laboratories has launched a generic version of phenylalanine hydroxylase activator Sapropterin Dihydrochloride Tablets, for oral use, in the US market. Sapropterin Dihydrochloride Tablets are indicated in the US for reducing blood phenylalanine (Phe) levels in adult and pediatric patients, aged one month and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- […]

Covis Group to acquire US biopharma company AMAG Pharmaceuticals

October 2, 2020 No Comment

Covis Group, a Luxembourg specialty pharma company, has agreed to acquire US biopharma company AMAG Pharmaceuticals for about $647 million, which includes the latter’s debt. As per the terms of the deal, Covis Group will acquire AMAG Pharmaceuticals for $13.75 per share in cash, or nearly $498 million. Covis Group is making the acquisition to […]

CStone Pharmaceuticals strikes $480m worth oncology deal with Pfizer

October 1, 2020 No Comment

US pharma giant Pfizer has entered into a collaboration deal worth up to $480 million with Chinese biopharma company CStone Pharmaceuticals to address the oncological needs in China. CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and precision medicines for cancer patients. The collaboration will be formed between the Chinese firm and Pfizer’s subsidiaries […]